利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

106 条记录 (耗时 0.054 秒)

    MCL-1 INHIBITORS AND METHODS OF USE THEREOF
    6.
    发明申请
    MCL-1 INHIBITORS AND METHODS OF USE THEREOF 有权

    公开(公告)号：US20170305926A1

    公开(公告)日：2017-10-26

    申请号：US15493210

    申请日：2017-04-21

    申请人： AstraZeneca AB

    发明人： Alexander HIRD ,  Wenzhan YANG ,  Daniel ROBBINS ,  Steven KAZMIRSKI ,  Dedong WU ,  Bo PENG ,  Jeffrey JOHANNES ,  Michelle LAMB

    IPC分类号： C07D497/22

    CPC分类号： C07D497/22 ,  C07D515/22

    摘要： Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

    Anititumoral ecteinascidin derivatives
    9.
    发明授权
    Anititumoral ecteinascidin derivatives 有权
    抗肿瘤抗坏血酸衍生物

    公开(公告)号：US07919493B2

    公开(公告)日：2011-04-05

    申请号：US11733606

    申请日：2007-04-10

    申请人： Maria Flores ,  Andres Francesh ,  Pilar Gallego ,  Jose Luis Chicharro ,  Maria Zarzuelo ,  Carolina Fernandez ,  Ignacio Manzanares

    发明人： Maria Flores ,  Andres Francesh ,  Pilar Gallego ,  Jose Luis Chicharro ,  Maria Zarzuelo ,  Carolina Fernandez ,  Ignacio Manzanares

    IPC分类号： C07D241/36 ,  A61K31/495 ,  A01N43/60

    CPC分类号： C07D515/22

    摘要： This invention relates to antitumoral ecteinascidin derivatives that contain a fused ecteinascidin five ring system with a 1,4-bridge having the structure of formula (VIa) or (VIb) as described herein and compounds in which the —NH2 or —OH of the 1,4-bridge is derivatized, and related pharmaceutical compositions and methods. Such ecteinascidin derivatives include, but are not limited to, those compounds having formula (XVIIb): in which R1 and R4 together form a group of formula (VIa) or (VIb) as described herein, and R5, R7, R8, R14a, R14b, R15, and R21 are as defined herein.

    摘要翻译： 本发明涉及含有具有如本文所述的结构式（VIa）或（VIb）的1,4桥的融合的ecteinidinidin五环系统的抗肿瘤抗坏血酸衍生物，其中1或2的-NH 2或-OH的化合物 ，4桥衍生化，相关药物组成和方法。 这样的黑皮质素衍生物包括但不限于具有式（XVIIb）的那些化合物：其中R 1和R 4一起形成本文所述的式（VIa）或（VIb）基团，并且R5，R7，R8，R14a， R14b，R15和R21如本文所定义。

    Hemisynthetic Method and New Compounds
    10.
    发明申请
    Hemisynthetic Method and New Compounds 有权
    半合成方法和新化合物

    公开(公告)号：US20080045713A1

    公开(公告)日：2008-02-21

    申请号：US11774890

    申请日：2007-07-09

    申请人： Carmen Cuevas ,  Marta Perez ,  Andres Francesch ,  Carolina Fernandez ,  Jose Chicharro ,  Pilar Gallego ,  Maria Zarzuelo ,  Fernando Calle ,  Ignacio Manzanares

    发明人： Carmen Cuevas ,  Marta Perez ,  Andres Francesch ,  Carolina Fernandez ,  Jose Chicharro ,  Pilar Gallego ,  Maria Zarzuelo ,  Fernando Calle ,  Ignacio Manzanares

    IPC分类号： C07D471/08 ,  C07D491/147

    CPC分类号： C07D471/18 ,  C07D471/22 ,  C07D491/22 ,  C07D515/22 ,  Y02P20/55

    摘要： Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically; R1 is an amidomethylene group or an aryloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.

    摘要翻译： 提供了制备具有式（XIV）的稠环结构的化合物的方法，其包含一个或多个由式（XVI）的21-氰基化合物开始的反应，其中通常; R 1是酰亚胺基或芳氧基亚甲基; R 5和R 8独立地选自-H，-OH或-OCOCH 2 OH，或R 5 O >和R 8均为酮，环A为对苯醌环; R 14a和R 14b都是-H臭氧是-H，另一个是-OH，-OCH 3或-OCH 3 2 3，或R 14a和R 14b共同形成酮基; R 15和R 18独立地选自-H或-OH，或R 5和R 8， 都是酮基，环A是对苯醌环。 在改性原料中，21-氰基可以被其它使用亲核试剂引入的基团所取代。